Lynne Pappas, MD
Psychiatry · Paradise, CANPI 1427069194
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $14,070 of the $17,630 with a category attached, or 79.8%. ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) accounts for 71.8% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2020 at $8,745 and has fallen 93.5% since, to $570 in 2025. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 235 payments — averaging $75.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$13K
- AbbVie$2K
- Indivior Inc.$776
- Otsuka America Pharmaceutical, Inc.$762
- Neurocrine Biosciences, Inc.$257
- Sunovion Pharmaceuticals Inc.$241
- plus $928 from 12 others
What the payments were for
- Speaking & faculty fees$14,07080%
- Food & beverage$3,41019%
- Education$1501%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 36 | $12,666 |
| AbbVie(2 entities) | 63 | $2,000 |
| Indivior Inc. | 10 | $776 |
| Otsuka America Pharmaceutical, Inc. | 65 | $762 |
| Neurocrine Biosciences, Inc. | 8 | $257 |
| Sunovion Pharmaceuticals Inc. | 14 | $241 |
| Teva Pharmaceuticals USA, Inc. | 10 | $197 |
| Johnson & Johnson | 7 | $194 |
| Axsome Therapeutics, Inc. | 2 | $133 |
| Idorsia Pharmaceuticals US Inc | 2 | $122 |
| Adlon Therapeutics L.p. | 3 | $55 |
| Eisai Inc. | 4 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
| Merck | 2 | $43 |
| Alkermes, Inc. | 3 | $37 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,630 in reported general payments places this provider in the 95th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| HetliozTasimelteon | 13 | $304,191 |
| Quetiapine Fumarate | 26 | $566 |
| Duloxetine Hcl | 25 | $167 |
| Fluoxetine Hcl | 18 | $93 |
| Lorazepam | 19 | $66 |
| Trazodone Hcl | 19 | $56 |
| Clonazepam | 16 | $52 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Paradise
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.